Co-expression of steroid hormone receptors (estrogen receptor α andor progesterone receptors) and H.docVIP

下载本文档

3
0
约2.82万字
约 16页
2018-06-25 发布于河南
举报
版权申诉

Co-expression of steroid hormone receptors (estrogen receptor α andor progesterone receptors) and H.doc

1、本文档共16页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Co-expression of steroid hormone receptors (estrogen receptor α andor progesterone receptors) and H

Co-expression of steroid hormone receptors (estrogen receptor α and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy Francisco E. Gagoa, Mariel A. Fanellib and Daniel R. Cioccab, , aGynecology Department, Medical School, National University of Cuyo, Parque Gral, San Martín, 5500 Mendoza, Argentina bLaboratory of Oncology, Institute of Experimental Medicine and Biology of Cuyo, National Research Council (IMBECU-CONICET) and Argentine Foundation for Cancer Research, Casilla de Correo, 855-5000 Mendoza, Argentina The Journal of Steroid Biochemistry and Molecular Biology Volume 98, Issue 1, January 2006, Pages 36-40 Abstract In breast cancer patients, the expression of steroid hormone receptors (HR:ERα/PR) appears inversely correlated with Her2/neu (not all reports agree on this negative correlation). Moreover, some but not all studies suggest that HR+/Her2/neu+ patients have a poor response to endocrine therapy, making this special group a matter of debate. In this prospective study we have analyzed the clinical outcome of our HR+/Her2/neu+ patients (n?=?51) selected from 516 consecutive stages I–II cases, with a follow-up 5–10 years (mean 7.3), treated with standard adjuvant therapy with tamoxifen (TAM) (TAM alone or TAM after chemotherapy). This group was compared with the HR+/Her-2/neu? patients (n?=?129) treated also with TAM. The tumor biopsies were studied by immunohistochemistry. We found that the association HR+/Her2/neu? was 2.5 times higher than the association HR+/Her2/neu+ (25% versus 9.9%, respectively). Our study also showed that the disease free survival (DFS) of the patients co-expressing HR and Her2/neu was significantly lower than those expressing HR but lacking of Her2/neu (p??0.001). A similar result was obtained when the overall survival (OS) was evaluated (p?=?0.001). All of these patients received hormone therapy with TAM, alone or after chemotherapy. When the anal